{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T10:39:12Z","timestamp":1752230352659,"version":"3.40.3"},"publisher-location":"Cham","reference-count":79,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783030793074"},{"type":"electronic","value":"9783030793081"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-3-030-79308-1_18","type":"book-chapter","created":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T01:02:45Z","timestamp":1640998965000},"page":"417-429","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Neurologic Toxicities of Immunotherapy"],"prefix":"10.1007","author":[{"given":"Rebecca A.","family":"Harrison","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazanin K.","family":"Majd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudhakar","family":"Tummala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,1]]},"reference":[{"key":"18_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2018.10.014","volume":"109","author":"J Rogado","year":"2019","unstructured":"Rogado, J., Sanchez-Torres, J. M., Romero-Laorden, N., et al. (2019). Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. European Journal of Cancer, 109, 21\u201327.","journal-title":"European Journal of Cancer"},{"key":"18_CR2","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.critrevonc.2018.07.010","volume":"130","author":"T Fujii","year":"2018","unstructured":"Fujii, T., Naing, A., Rolfo, C., & Hajjar, J. (2018). Biomarkers of response to immune checkpoint blockade in cancer treatment. Critical Reviews in Oncology\/Hematology, 130, 108\u2013120.","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"18_CR3","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/ana.25708","volume":"87","author":"D Dubey","year":"2020","unstructured":"Dubey, D., David, W. S., Reynolds, K. L., et al. (2020). Severe neurological toxicity of immune checkpoint inhibitors: Growing Spectrum. Annals of Neurology, 87, 659\u2013669.","journal-title":"Annals of Neurology"},{"key":"18_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","volume":"73","author":"S Cuzzubbo","year":"2017","unstructured":"Cuzzubbo, S., Javeri, F., Tissier, M., et al. (2017). Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. European Journal of Cancer, 73, 1\u20138.","journal-title":"European Journal of Cancer"},{"key":"18_CR5","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson, J. S., Palomba, M. L., Gordon, L. I., et al. (2020). Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study. Lancet, 396, 839\u2013852.","journal-title":"Lancet"},{"key":"18_CR6","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L., Laetsch, T. W., Buechner, J., et al. (2018). Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. The New England Journal of Medicine, 378, 439\u2013448.","journal-title":"The New England Journal of Medicine"},{"key":"18_CR7","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C., Anderson, L. D., Jr., Shah, N., et al. (2021). Idecabtagene Vicleucel in relapsed and refractory multiple myeloma. The New England Journal of Medicine, 384, 705\u2013716.","journal-title":"The New England Journal of Medicine"},{"key":"18_CR8","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S., Locke, F. L., Bartlett, N. L., et al. (2017). Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. The New England Journal of Medicine, 377, 2531\u20132544.","journal-title":"The New England Journal of Medicine"},{"key":"18_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster, S. J., Bishop, M. R., Tam, C. S., et al. (2019). Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. The New England Journal of Medicine, 380, 45\u201356.","journal-title":"The New England Journal of Medicine"},{"key":"18_CR10","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang, M., Munoz, J., Goy, A., et al. (2020). KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. The New England Journal of Medicine, 382, 1331\u20131342.","journal-title":"The New England Journal of Medicine"},{"key":"18_CR11","doi-asserted-by":"crossref","unstructured":"Naing, A., Hajjar, J., Gulley, J. L., et al. (2020). Strategies for improving the management of immune-related adverse events. Journal for Immunotherapy of Cancer, 8.","DOI":"10.1136\/jitc-2020-001754"},{"key":"18_CR12","doi-asserted-by":"crossref","unstructured":"Mendoza, T., Sheshadri, A., Altan, M., et al. (2020). Evaluating the psychometric properties of the immunotherapy module of the MD Anderson symptom inventory. Journal for Immunotherapy of Cancer, 8.","DOI":"10.1136\/jitc-2020-000931"},{"key":"18_CR13","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S., O'Day, S. J., McDermott, D. F., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine, 363, 711\u2013723.","journal-title":"The New England Journal of Medicine"},{"key":"18_CR14","doi-asserted-by":"crossref","unstructured":"Choi, Y., Shi, Y., Haymaker, C. L., Naing, A., Ciliberto, G., & Hajjar, J. (2020). T-cell agonists in cancer immunotherapy. Journal for Immunotherapy of Cancer, 8.","DOI":"10.1136\/jitc-2020-000966"},{"key":"18_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s11912-019-0859-2","volume":"21","author":"PC Pan","year":"2019","unstructured":"Pan, P. C., & Haggiagi, A. (2019). Neurologic immune-related adverse events associated with immune checkpoint inhibition. Current Oncology Reports, 21, 108.","journal-title":"Current Oncology Reports"},{"key":"18_CR16","first-page":"119","volume":"78","author":"O Maeda","year":"2016","unstructured":"Maeda, O., Yokota, K., Atsuta, N., Katsuno, M., Akiyama, M., & Ando, Y. (2016). Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis. Nagoya Journal of Medical Science, 78, 119\u2013122.","journal-title":"Nagoya Journal of Medical Science"},{"key":"18_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40425-014-0035-z","volume":"2","author":"C Kyi","year":"2014","unstructured":"Kyi, C., Carvajal, R. D., Wolchok, J. D., & Postow, M. A. (2014). Ipilimumab in patients with melanoma and autoimmune disease. Journal for Immunotherapy of Cancer, 2, 35.","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"18_CR18","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1212\/WNL.51.6.1738","volume":"51","author":"MD Weiss","year":"1998","unstructured":"Weiss, M. D., Luciano, C. A., Semino-Mora, C., Dalakas, M. C., & Quarles, R. H. (1998). Molecular mimicry in chronic inflammatory demyelinating polyneuropathy and melanoma. Neurology, 51, 1738\u20131741.","journal-title":"Neurology"},{"key":"18_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/jnci\/78.1.45","volume":"78","author":"T Tsuchida","year":"1987","unstructured":"Tsuchida, T., Saxton, R. E., Morton, D. L., & Irie, R. F. (1987). Gangliosides of human melanoma. Journal of the National Cancer Institute, 78, 45\u201354.","journal-title":"Journal of the National Cancer Institute"},{"key":"18_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.lungcan.2017.11.019","volume":"115","author":"K Sato","year":"2018","unstructured":"Sato, K., Akamatsu, H., Murakami, E., et al. (2018). Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer (Amsterdam, Netherlands), 115, 71\u201374.","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"18_CR21","doi-asserted-by":"crossref","unstructured":"Bomze, D., Hasan Ali, O., Bate, A., & Flatz, L. (2019). Association between immune-related adverse events during anti-PD-1 therapy and tumor mutational burden. JAMA Oncology.","DOI":"10.1001\/jamaoncol.2019.3221"},{"key":"18_CR22","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000006278","volume":"91","author":"M Algaeed","year":"2018","unstructured":"Algaeed, M., Mukharesh, L., Heinzelmann, M., & Kaminski, H. J. (2018). Pearls & Oy-sters: Pembrolizumab-induced myasthenia gravis. Neurology, 91, e1365\u2013e13e7.","journal-title":"Neurology"},{"key":"18_CR23","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","volume":"82","author":"D Makarious","year":"2017","unstructured":"Makarious, D., Horwood, K., & Coward, J. I. G. (2017). Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors. European Journal of Cancer (Oxford, England: 1990), 82, 128\u2013136.","journal-title":"European Journal of Cancer (Oxford, England: 1990)"},{"key":"18_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.25141","volume":"54","author":"KH Lau","year":"2016","unstructured":"Lau, K. H., Kumar, A., Yang, I. H., & Nowak, R. J. (2016). Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. Muscle & Nerve, 54, 157\u2013161.","journal-title":"Muscle & Nerve"},{"key":"18_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3988\/jcn.2018.14.1.115","volume":"14","author":"SY Huh","year":"2018","unstructured":"Huh, S. Y., Shin, S. H., Kim, M. K., Lee, S. Y., Son, K. H., & Shin, H. Y. (2018). Emergence of myasthenia gravis with myositis in a patient treated with Pembrolizumab for Thymic Cancer. Journal of Clinical Neurology (Seoul, Korea), 14, 115\u2013117.","journal-title":"Journal of Clinical Neurology (Seoul, Korea)"},{"key":"18_CR26","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/cas.12961","volume":"107","author":"T Kimura","year":"2016","unstructured":"Kimura, T., Fukushima, S., Miyashita, A., et al. (2016). Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Science, 107, 1055\u20131058.","journal-title":"Cancer Science"},{"key":"18_CR27","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/mus.25163","volume":"54","author":"P Polat","year":"2016","unstructured":"Polat, P., & Donofrio, P. D. (2016). Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer. Muscle & Nerve, 54, 507.","journal-title":"Muscle & Nerve"},{"key":"18_CR28","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","volume":"74","author":"JC Kao","year":"2017","unstructured":"Kao, J. C., Liao, B., Markovic, S. N., et al. (2017). Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurology, 74, 1216\u20131222.","journal-title":"JAMA Neurology"},{"key":"18_CR29","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi, J. J., Salem, J. E., Sosman, J. A., Lebrun-Vignes, B., & Johnson, D. B. (2018). Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet (London, England), 391, 933.","journal-title":"Lancet (London, England)"},{"key":"18_CR30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S0003-4975(00)01595-2","volume":"70","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki, A., 3rd, Barohn, R. J., Ernstoff, R. M., et al. (2000). Myasthenia gravis: Recommendations for clinical research standards. Task force of the medical scientific advisory Board of the Myasthenia Gravis Foundation of America. The Annals of Thoracic Surgery, 70, 327\u2013334.","journal-title":"The Annals of Thoracic Surgery"},{"key":"18_CR31","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1200\/JOP.18.00005","volume":"14","author":"JR Brahmer","year":"2018","unstructured":"Brahmer, J. R., Lacchetti, C., & Thompson, J. A. (2018). Management of Immune-Related Adverse Events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline summary. Journal of Oncology Practice\/ American Society of Clinical Oncology, 14, 247\u2013249.","journal-title":"Journal of Oncology Practice\/ American Society of Clinical Oncology"},{"key":"18_CR32","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/j.1875-9114.1997.tb03085.x","volume":"17","author":"RW Barrons","year":"1997","unstructured":"Barrons, R. W. (1997). Drug-induced neuromuscular blockade and myasthenia gravis. Pharmacotherapy, 17, 1220\u20131232.","journal-title":"Pharmacotherapy"},{"key":"18_CR33","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1017\/S0317167100007939","volume":"36","author":"G Hunter","year":"2009","unstructured":"Hunter, G., Voll, C., & Robinson, C. A. (2009). Autoimmune inflammatory myopathy after treatment with ipilimumab. The Canadian Journal of Neurological Sciences, 36, 518\u2013520.","journal-title":"The Canadian Journal of Neurological Sciences"},{"key":"18_CR34","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","volume":"106","author":"A Moreira","year":"2019","unstructured":"Moreira, A., Loquai, C., Pfohler, C., et al. (2019). Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. European Journal of Cancer (Oxford, England: 1990), 106, 12\u201323.","journal-title":"European Journal of Cancer (Oxford, England: 1990)"},{"key":"18_CR35","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s11060-018-2752-5","volume":"137","author":"A Fellner","year":"2018","unstructured":"Fellner, A., Makranz, C., Lotem, M., et al. (2018). Neurologic complications of immune checkpoint inhibitors. Journal of Neuro-Oncology, 137, 601\u2013609.","journal-title":"Journal of Neuro-Oncology"},{"key":"18_CR36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11910-018-0810-1","volume":"18","author":"C Astaras","year":"2018","unstructured":"Astaras, C., de Micheli, R., Moura, B., Hundsberger, T., & Hottinger, A. F. (2018). Neurological adverse events associated with immune checkpoint inhibitors: Diagnosis and management. Current Neurology and Neuroscience Reports, 18, 3.","journal-title":"Current Neurology and Neuroscience Reports"},{"key":"18_CR37","first-page":"77","volume":"38","author":"I Thaipisuttikul","year":"2015","unstructured":"Thaipisuttikul, I., Chapman, P., & Avila, E. K. (2015). Peripheral neuropathy associated with ipilimumab: A report of 2 cases. Journal of Immunotherapy (Hagerstown, Md: 1997), 38, 77\u201379.","journal-title":"Journal of Immunotherapy (Hagerstown, Md: 1997)"},{"key":"18_CR38","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/annonc\/mdr028","volume":"22","author":"S Wilgenhof","year":"2011","unstructured":"Wilgenhof, S., & Neyns, B. (2011). Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Annals of Oncology, 22, 991\u2013993.","journal-title":"Annals of Oncology"},{"key":"18_CR39","doi-asserted-by":"publisher","first-page":"e1093","DOI":"10.1212\/WNL.0000000000008091","volume":"93","author":"D Dubey","year":"2019","unstructured":"Dubey, D., David, W. S., Amato, A. A., et al. (2019). Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology, 93, e1093\u2013ee103.","journal-title":"Neurology"},{"key":"18_CR40","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s40425-019-0748-0","volume":"7","author":"CA Gao","year":"2019","unstructured":"Gao, C. A., Weber, U. M., Peixoto, A. J., & Weiss, S. A. (2019). Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma. Journal for Immunotherapy of Cancer, 7, 262.","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"18_CR41","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1634\/theoncologist.2016-0487","volume":"22","author":"J Larkin","year":"2017","unstructured":"Larkin, J., Chmielowski, B., Lao, C. D., et al. (2017). Neurologic serious adverse events associated with Nivolumab plus Ipilimumab or Nivolumab alone in advanced melanoma, including a case series of encephalitis. The Oncologist, 22, 709\u2013718.","journal-title":"The Oncologist"},{"key":"18_CR42","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1177\/0194599815606701","volume":"153","author":"AL Altman","year":"2015","unstructured":"Altman, A. L., Golub, J. S., Pensak, M. L., & Samy, R. N. (2015). Bilateral facial palsy following Ipilimumab infusion for melanoma. Otolaryngology\u2013Head and Neck Surgery, 153, 894\u2013895.","journal-title":"Otolaryngology\u2013Head and Neck Surgery"},{"key":"18_CR43","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1158\/2326-6066.CIR-15-0141","volume":"3","author":"C Maurice","year":"2015","unstructured":"Maurice, C., Schneider, R., Kiehl, T. R., et al. (2015). Subacute CNS demyelination after treatment with Nivolumab for melanoma. Cancer Immunology Research, 3, 1299\u20131302.","journal-title":"Cancer Immunology Research"},{"key":"18_CR44","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1007\/s12094-019-02060-8","volume":"21","author":"CR Garcia","year":"2019","unstructured":"Garcia, C. R., Jayswal, R., Adams, V., Anthony, L. B., & Villano, J. L. (2019). Multiple sclerosis outcomes after cancer immunotherapy. Clinical & Translational Oncology, 21, 1336\u20131342.","journal-title":"Clinical & Translational Oncology"},{"key":"18_CR45","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1177\/1352458514549403","volume":"21","author":"EJ Gettings","year":"2015","unstructured":"Gettings, E. J., Hackett, C. T., & Scott, T. F. (2015). Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma. Multiple Sclerosis (Houndmills, Basingstoke, England), 21, 670.","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"key":"18_CR46","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3121\/cmr.2019.1417","volume":"17","author":"Z Zafar","year":"2019","unstructured":"Zafar, Z., Vogler, C., Hudali, T., & Bhattarai, M. (2019). Nivolumab-associated acute demyelinating encephalitis: A case report and literature review. Clinical Medicine & Research, 17, 29\u201333.","journal-title":"Clinical Medicine & Research"},{"key":"18_CR47","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1212\/WNL.0000000000002594","volume":"86","author":"Y Cao","year":"2016","unstructured":"Cao, Y., Nylander, A., Ramanan, S., et al. (2016). CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment. Neurology, 86, 1553\u20131556.","journal-title":"Neurology"},{"key":"18_CR48","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","volume":"34","author":"R Nanda","year":"2016","unstructured":"Nanda, R., Chow, L. Q., Dees, E. C., et al. (2016). Pembrolizumab in patients with advanced triple-negative breast Cancer: Phase Ib KEYNOTE-012 study. Journal of Clinical Oncology, 34, 2460\u20132467.","journal-title":"Journal of Clinical Oncology"},{"key":"18_CR49","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1136\/practneurol-2012-000447","volume":"13","author":"I Bot","year":"2013","unstructured":"Bot, I., Blank, C. U., Boogerd, W., & Brandsma, D. (2013). Neurological immune-related adverse events of ipilimumab. Practical Neurology, 13, 278\u2013280.","journal-title":"Practical Neurology"},{"key":"18_CR50","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1097\/WCO.0000000000000503","volume":"30","author":"M Touat","year":"2017","unstructured":"Touat, M., Talmasov, D., Ricard, D., & Psimaras, D. (2017). Neurological toxicities associated with immune-checkpoint inhibitors. Current Opinion in Neurology, 30, 659\u2013668.","journal-title":"Current Opinion in Neurology"},{"key":"18_CR51","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1159\/000477162","volume":"10","author":"S Schneider","year":"2017","unstructured":"Schneider, S., Potthast, S., Komminoth, P., Schwegler, G., & Bohm, S. (2017). PD-1 checkpoint inhibitor associated autoimmune encephalitis. Case Reports in Oncology, 10, 473\u2013478.","journal-title":"Case Reports in Oncology"},{"key":"18_CR52","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1155\/2019\/7183747","volume":"2019","author":"G Lima","year":"2019","unstructured":"Lima, G., Kahn, A., Sama, S., & Savage, J. (2019). Aseptic meningitis as an immune-related adverse event after Pembrolizumab. Case Reports in Oncological Medicine, 2019, 2.","journal-title":"Case Reports in Oncological Medicine"},{"key":"18_CR53","doi-asserted-by":"publisher","first-page":"100012","DOI":"10.1016\/j.jtocrr.2020.100012","volume":"1","author":"R Toyozawa","year":"2020","unstructured":"Toyozawa, R., Haratake, N., Toyokawa, G., et al. (2020). Atezolizumab-induced aseptic meningitis in patients with NSCLC. JTO Clinical and Research Reports, 1, 100012.","journal-title":"JTO Clinical and Research Reports"},{"key":"18_CR54","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3988\/jcn.2019.15.2.259","volume":"15","author":"A Kim","year":"2019","unstructured":"Kim, A., Keam, B., Cheun, H., Lee, S. T., Gook, H. S., & Han, M. K. (2019). Immune-checkpoint-inhibitor-induced severe autoimmune encephalitis treated by steroid and intravenous immunoglobulin. Journal of Clinical Neurology, 15, 259\u2013261.","journal-title":"Journal of Clinical Neurology"},{"key":"18_CR55","doi-asserted-by":"publisher","first-page":"e439","DOI":"10.1212\/NXI.0000000000000439","volume":"5","author":"AF Hottinger","year":"2018","unstructured":"Hottinger, A. F., de Micheli, R., Guido, V., Karampera, A., Hagmann, P., & Du Pasquier, R. (2018). Natalizumab may control immune checkpoint inhibitor-induced limbic encephalitis. Neurology(R) Neuroimmunology & Neuroinflammation, 5, e439.","journal-title":"Neurology(R) Neuroimmunology & Neuroinflammation"},{"key":"18_CR56","doi-asserted-by":"crossref","unstructured":"Chung, M., Jaffer, M., Verma, N., Mokhtari, S., Ramsakal, A., & Peguero, E. (2019). Immune checkpoint inhibitor induced anti-glutamic acid decarboxylase 65 (anti-GAD 65) limbic encephalitis responsive to intravenous immunoglobulin and plasma exchange. Journal of Neurology.","DOI":"10.1007\/s00415-019-09666-6"},{"key":"18_CR57","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1001\/jamaneurol.2016.1399","volume":"73","author":"TJ Williams","year":"2016","unstructured":"Williams, T. J., Benavides, D. R., Patrice, K. A., et al. (2016). Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurology, 73, 928\u2013933.","journal-title":"JAMA Neurology"},{"key":"18_CR58","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/acn3.547","volume":"5","author":"R Wilson","year":"2018","unstructured":"Wilson, R., Menassa, D. A., Davies, A. J., et al. (2018). Seronegative antibody-mediated neurology after immune checkpoint inhibitors. Annals of Clinical and Translational Neurology, 5, 640\u2013645.","journal-title":"Annals of Clinical and Translational Neurology"},{"key":"18_CR59","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/neuonc\/nou001","volume":"16","author":"B Liao","year":"2014","unstructured":"Liao, B., Shroff, S., Kamiya-Matsuoka, C., & Tummala, S. (2014). Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-Oncology, 16, 589\u2013593.","journal-title":"Neuro-Oncology"},{"key":"18_CR60","doi-asserted-by":"publisher","first-page":"e0160221","DOI":"10.1371\/journal.pone.0160221","volume":"11","author":"N Abdel-Wahab","year":"2016","unstructured":"Abdel-Wahab, N., Shah, M., & Suarez-Almazor, M. E. (2016). Adverse events associated with immune checkpoint blockade in patients with cancer: A systematic review of case reports. PLoS One, 11, e0160221.","journal-title":"PLoS One"},{"key":"18_CR61","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","volume":"37","author":"A Daxini","year":"2018","unstructured":"Daxini, A., Cronin, K., & Sreih, A. G. (2018). Vasculitis associated with immune checkpoint inhibitors-a systematic review. Clinical Rheumatology, 37, 2579\u20132584.","journal-title":"Clinical Rheumatology"},{"key":"18_CR62","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W., Santomasso, B. D., Locke, F. L., et al. (2019). ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biology of Blood and Marrow Transplantation, 25, 625\u2013638.","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"18_CR63","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso, B. D., Park, J. H., Salloum, D., et al. (2018). Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discovery, 8, 958\u2013971.","journal-title":"Cancer Discovery"},{"key":"18_CR64","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J. H., Riviere, I., Gonen, M., et al. (2018). Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. The New England Journal of Medicine, 378, 449\u2013459.","journal-title":"The New England Journal of Medicine"},{"key":"18_CR65","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee, D. W., Gardner, R., Porter, D. L., et al. (2014). Current concepts in the diagnosis and management of cytokine release syndrome. Blood, 124, 188\u2013195.","journal-title":"Blood"},{"key":"18_CR66","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu, S. S., Tummala, S., Kebriaei, P., et al. (2018). Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nature Reviews. Clinical Oncology, 15, 47\u201362.","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"18_CR67","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer, J. R., Lacchetti, C., Schneider, B. J., et al. (2018). Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology, 36, 1714\u20131768.","journal-title":"Journal of Clinical Oncology"},{"key":"18_CR68","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","volume":"133","author":"P Karschnia","year":"2019","unstructured":"Karschnia, P., Jordan, J. T., Forst, D. A., et al. (2019). Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood, 133, 2212\u20132221.","journal-title":"Blood"},{"key":"18_CR69","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1093\/brain\/awz053","volume":"142","author":"DB Rubin","year":"2019","unstructured":"Rubin, D. B., Danish, H. H., Ali, A. B., et al. (2019). Neurological toxicities associated with chimeric antigen receptor T-cell therapy. Brain, 142, 1334\u20131348.","journal-title":"Brain"},{"key":"18_CR70","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/nrclinonc.2018.19","volume":"15","author":"DT Teachey","year":"2018","unstructured":"Teachey, D. T., Bishop, M. R., Maloney, D. G., & Grupp, S. A. (2018). Toxicity management after chimeric antigen receptor T cell therapy: One size does not fit \u2018ALL\u2019. Nature Reviews Clinical Oncology, 15, 218.","journal-title":"Nature Reviews Clinical Oncology"},{"key":"18_CR71","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust, J., Hay, K. A., Hanafi, L. A., et al. (2017). Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discovery, 7, 1404\u20131419.","journal-title":"Cancer Discovery"},{"key":"18_CR72","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster, S. J., Svoboda, J., Chong, E. A., et al. (2017). Chimeric antigen receptor T cells in refractory B-cell lymphomas. The New England Journal of Medicine, 377, 2545\u20132554.","journal-title":"The New England Journal of Medicine"},{"key":"18_CR73","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1093\/jnen\/nly064","volume":"77","author":"M Torre","year":"2018","unstructured":"Torre, M., Solomon, I. H., Sutherland, C. L., et al. (2018). Neuropathology of a case with fatal CAR T-cell-associated cerebral edema. Journal of Neuropathology and Experimental Neurology, 77, 877\u2013882.","journal-title":"Journal of Neuropathology and Experimental Neurology"},{"key":"18_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaneurol.2020.2703","volume":"77","author":"DB Rubin","year":"2020","unstructured":"Rubin, D. B., Al Jarrah, A., Li, K., et al. (2020). Clinical predictors of neurotoxicity after chimeric antigen receptor T-cell therapy. JAMA Neurology, 77, 1\u20137.","journal-title":"JAMA Neurology"},{"issue":"Suppl 1","key":"18_CR75","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hon.2595","volume":"37","author":"SS Neelapu","year":"2019","unstructured":"Neelapu, S. S. (2019). Managing the toxicities of CAR T-cell therapy. Hematological Oncology, 37(Suppl 1), 48\u201352.","journal-title":"Hematological Oncology"},{"key":"18_CR76","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila, M. L., Riviere, I., Wang, X., et al. (2014). Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Science Translational Medicine, 6, 224ra25.","journal-title":"Science Translational Medicine"},{"key":"18_CR77","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-020-0280-y","volume":"10","author":"S Liu","year":"2020","unstructured":"Liu, S., Deng, B., Yin, Z., et al. (2020). Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia. Blood Cancer Journal, 10, 15.","journal-title":"Blood Cancer Journal"},{"key":"18_CR78","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1182\/blood.2019001463","volume":"134","author":"RA Gardner","year":"2019","unstructured":"Gardner, R. A., Ceppi, F., Rivers, J., et al. (2019). Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood, 134, 2149\u20132158.","journal-title":"Blood"},{"key":"18_CR79","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1158\/2159-8290.CD-17-1368","volume":"8","author":"A Taraseviciute","year":"2018","unstructured":"Taraseviciute, A., Tkachev, V., Ponce, R., et al. (2018). Chimeric antigen receptor T cell-mediated neurotoxicity in nonhuman primates. Cancer Discovery, 8, 750\u2013763.","journal-title":"Cancer Discovery"}],"container-title":["Advances in Experimental Medicine and Biology","Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-79308-1_18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T02:48:31Z","timestamp":1700016511000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-030-79308-1_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9783030793074","9783030793081"],"references-count":79,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-79308-1_18","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"type":"print","value":"0065-2598"},{"type":"electronic","value":"2214-8019"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"1 January 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}